Literature DB >> 24565533

Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.

Olivera Markovic1, Lazar Popovic2, Dragomir Marisavljevic3, Darjana Jovanovic2, Branka Filipovic3, Dejana Stanisavljevic4, Gorana Matovina-Brko2, Jelena Hajder5, Tatjana Matkovic5, Radmila Živkovic5, Natasa Stanisavljevic5, Milena Todorović6, Dragana Petrovic5, Biljana Mihaljevic6.   

Abstract

BACKGROUND: The combination of absolute lymphocyte count (ALC) and absolute monocyte count (AMC) at diagnosis has prognostic relevance in patients with diffuse large B cell lymphoma (DLBCL). AIMS: The present study was designed to investigate the prognostic significance of ALC and AMC and to determine whether ALC/AMC ratio or ALC/AMC prognostic score is better predictor of outcome in DLBCL.
METHODS: We retrospectively analyzed the prognostic significance of ALC and AMC, ALC/AMC ratio and ALC/AMC prognostic score at diagnosis in 222 DLBCL patients treated with R-CHOP.
RESULTS: ROC analysis showed that optimal cut-off values of AMC and ALC/AMC ratio with the best sensitivity and specificity were 0.59×10(9)/L and 2.8, respectively. Cut-off of ALC was determined according to the literature data (1×10(9)/L). Low ALC, high AMC, low ALC/AMC ratio and high ALC/AMC prognostic score were in significant association with lower rate of therapy response and survival. In contrast, these parameters were not in significant correlation with relapse rate. The patients with low ALC, "high" AMC, low ALC/AMC ratio and high ALC/AMC prognostic score at diagnosis had significantly shorter EFS and OS. In multivariate analysis all tested parameters (ALC, AMC, ALC/AMC prognostic score and ALC/AMC ratio) are independent risk factors along with "bulky" disease and IPI.
CONCLUSION: All tested parameters (ALC, AMC, ALC/AMC score and ALC/AMC ratio) may be useful prognostic factors in DLBCL patients. ALC/AMC score has a slight advantage as it allows the classification of patients into three prognostic groups. Further studies are needed to determine which of these parameters has the highest predictive value.
Copyright © 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALC/AMC prognostic score; ALC/AMC ratio; Absolute lymphocyte and monocyte counts; Diffuse large B cell lymphoma

Mesh:

Year:  2014        PMID: 24565533     DOI: 10.1016/j.ejim.2014.01.019

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  13 in total

1.  The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.

Authors:  Linghong Guo; Honghong Ren; Lutong Pu; Xingyu Zhu; Yin Liu; Xuelei Ma
Journal:  Cancer Manag Res       Date:  2020-08-13       Impact factor: 3.989

2.  Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.

Authors:  Yu-Wen Wang; Xavier Cheng-Hong Tsai; Hsin-An Hou; Feng-Ming Tien; Jia-Hau Liu; Wen-Chien Chou; Bor-Sheng Ko; Yu-Wen Chen; Chien-Chin Lin; Chieh-Lung Cheng; Min-Yen Lo; Yun-Chu Lin; Li-Chun Lu; Shang-Ju Wu; Sung-Hsin Kuo; Ruey-Long Hong; Tai-Chung Huang; Ming Yao
Journal:  Ann Hematol       Date:  2021-11-11       Impact factor: 3.673

3.  Monocyte-to-Lymphocyte Ratio in the Diagnosis of Lymphoma in Adult Patients.

Authors:  Naoko Kamiya; Yukiko Ishikawa; Kazuhiko Kotani; Shuji Hatakeyama; Masami Matsumura
Journal:  Int J Gen Med       Date:  2022-04-20

4.  A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.

Authors:  Jun Cai; Xiaopeng Tian; Shuyun Ma; Liye Zhong; Wenyu Li; Liang Wang; Linlang Guo; Zhihua Li; Yudan Wu; Guangzheng Zhong; Huiqiang Huang; Zhongjun Xia; Yi Xia; Panpan Liu; Ning Su; Yu Fang; Yuchen Zhang; Qingqing Cai
Journal:  Br J Cancer       Date:  2021-05-19       Impact factor: 7.640

5.  Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.

Authors:  Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; William J Hogan; Svetomir N Markovic
Journal:  J Hematol Oncol       Date:  2015-07-03       Impact factor: 17.388

6.  Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Authors:  Wen-Kai Xia; Qing-Feng Lin; Dong Shen; Zhi-Li Liu; Jun Su; Wei-Dong Mao
Journal:  FEBS Open Bio       Date:  2016-05-04       Impact factor: 2.693

Review 7.  Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis.

Authors:  Liangyou Gu; Hongzhao Li; Luyao Chen; Xin Ma; Xintao Li; Yu Gao; Yu Zhang; Yongpeng Xie; Xu Zhang
Journal:  Oncotarget       Date:  2016-05-31

8.  Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.

Authors:  Shujuan Zhou; Linglong Xu; Yongyong Ma; Liyuan Tang; Yu Zhang; Yifen Shi; Lan Sun; Yi Chen; Bin Liang; Yuhong Zhou; Kang Yu; Jianping Shen
Journal:  Oncotarget       Date:  2017-03-21

9.  Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports.

Authors:  Hui-Ling Sun; Yu-Qin Pan; Bang-Shun He; Zhen-Lin Nie; Kang Lin; Hong-Xin Peng; William C Cho; Shu-Kui Wang
Journal:  Onco Targets Ther       Date:  2016-05-20       Impact factor: 4.147

10.  Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes.

Authors:  Vivek Naranbhai; Helen A Fletcher; Rachel Tanner; Matthew K O'Shea; Helen McShane; Benjamin P Fairfax; Julian C Knight; Adrian V S Hill
Journal:  EBioMedicine       Date:  2015-11       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.